Dr BARTHELEMY Philippe

Real-World Outcomes of [Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer.

Bailly C, Vija L, Somme F, Massard V, Barthélémy P, Giraudet AL, Godbert Y, Fléchon A, Girault S, Abadie-Lacourtoisie S, Viala C, Douillet A, Chêne S, Olivier P, Roubaud G

J Nucl Med. 2026 08 6;:

[Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, Beltran H, Kramer G, Mahammedi H, Eiber M, Gupta S, Castellano D, Hauke R, Kim H, Kwak C, Pang ST, Barthélémy P, Dai D, Lee JL, Nordquist L, Szmulewitz RZ, Wiechno P, Yovine A, Smith L, Bouillaud E, Sakharova O, Morris MJ,

Lancet. 2026 08 6;:

Squamous cell carcinoma of the bladder: Current evidence, therapeutic challenges, and research perspectives from the French AVENTUR group.

Mercier J, Cornillon P, Barthélémy P, Leon P, Fontugne J, Guimas V, Bouleftour W, Olivier L, Affi R, Pouessel D, Culine S, Roumiguié M, Mahammedi H, Thibault C, Moinard-Butot F

Crit Rev Oncol Hematol. 2026 07 28;225:105505

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suárez C, Maroto JP, Grünwald V, Oosting S, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Stöhr C, Hartmann A, Bergmann L,

Cancer Treat Res Commun. 2026 07 18;48:101319

De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?

Moinard-Butot F, Nannini S, Gravis G, Pautas M, Pignot G, Barthélémy P

Clin Genitourin Cancer. 2026 06 21;24(6):102605

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suárez C, Maroto JP, Grünwald V, Oosting S, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Bergmann L,

Eur J Cancer. 2026 05 27;243:116816

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Thibault C, Bennamoun M, Fléchon A, Gravis G, Pouessel D, Combe P, Borchiellini D, Loriot Y, Laguerre B, Barthélémy P, Huillard O, Gross-Goupil M, Le Roy A, Jaffrelot L, Cancel M, Audenet F, Belhouari H, Kaci G, Lepicard E, Vernerey D, Henriques J, Oudard S

J Clin Oncol. 2026 05 26;:JCO2503045

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Amrane K, Campedel L, Moinard-Butot F, Gout M, Mahammedi H, Bennamoun M, Herrmann T, Gabriel PE, Pouessel D, Roulleaux-Dugage M, Thibault C, Cancel M, Flechon A, Huillard O, Abbar B, Borchiellini D, Doublet L, Augusto-Pelegrin L, Boughalem E, Cornillon P, Dumont C, Barthélémy P

Cancer Immunol Immunother. 2026 05 24;:

Achieving no evidence of disease in metastatic renal cell carcinoma: Consolidative nephrectomy vs ablative therapy.

Zelmar A, Gaillard V, Cazzato RL, Tricard T, Barthelemy P, Moinard-Butot F, Gangi A, Lang H

Fr J Urol. 2026 05 20;36(6-7):103132

Spontaneous Regression of Clear Cell Renal Cell Carcinoma Metastases or Immune Restoration?

Vacheret C, Moinard-Butot F, Reberol L, Ciccolini A, Cazzato RL, Barthélémy P

Curr Oncol. 2026 05 10;33(5):

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

Negrier S, Mourey L, Dalban C, Gross-Goupil M, Fléchon A, Escudier B, Barthélémy P, Oudard S, Colomba E, Thibault C, Ravaud A, Chevreau C, Boyle HJ, Blanc E, Chabaud S, Pérol D, Albiges L, Flippot R,

Eur J Cancer. 2026 04 1;239:116712

Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study.

Moinard-Butot F, Barbe-Richaud JB, Baudry E, Pierard L, Amrane K, Maillet D, Barthélémy P

Urol Oncol. 2026 02 28;44(5):111036

PARP Inhibitors Combined with Abiraterone Overcome Resistance in Metastatic Castration-Resistant Prostate Cancer Independently of Androgen Receptor.

Mallah H, Soultani S, Diabasana Z, Lindner V, Barthélémy P, Idoux-Gillet Y, Massfelder T

Cancers (Basel). 2026 02 9;18(4):

Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.

Blanchet B, Puszkiel A, Jouinot A, Bennamoun M, Maillet D, Borchiellini D, Laguerre B, Pannier D, Gross-Goupil M, Chevreau C, Barthélémy P, Tournigand C, Coquan E, Gravis G, Lepicard E, Fridman WH, Sautes-Fridman C, Oudard S, Sun CM, Vano YA

Br J Cancer. 2026 02 6;:

The effectiveness of telemonitoring, either self-administered or professionally assisted, in cancer care management: a descriptive, retrospective, observational cohort study.

Martin S, Fritsch A, Jouannaud C, Martin-Babau J, Mennecier B, Slimano F, Bordeau A, Guéroult-Accolas L, Delcour B, Raymond E, Renet S, Sonntag-Mottier C, Morel A, Courouve L, Detournay B, Barthélémy P

Support Care Cancer. 2026 01 15;34(2):98

Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma.

Harba A, Moinard-Butot F, Auclin E, Barthélémy P, Noel J, Dumont C, Gauthier H, Huillard O, Jaffrelot L, Seisen T, Joly C, Tournigand C, Bennamoun M, Roulleaux-Dugage M, Cancel M, Heurtier V, Lardjani H, Oudard S, Thibault C

Clin Genitourin Cancer. 2026 01 14;:102506

Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004).

Mjaess G, Quackels T, Fantoni JC, Tricard T, Marcq G, Blanc J, Barthelemy P, Carnot A, Sideris S, Awada A, Chanza NM, Peltier A, Albisinni S, Diamand R, Roumeguère T

World J Urol. 2026 01 13;44(1):90

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Fizazi K, Saad F, Alonso-Gordoa T, Żurawski B, Barthélémy P, Voog E, Javier Cutuli H, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhöfer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK

Lancet Oncol. 2026 01;27(1):68-78

Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).

Morgans AK, Chehrazi-Raffle A, Niazi T, Shore ND, Ross AE, Røder A, Gomes AJ, Supiot S, Barthélémy P, Hatano K, Ruiz CBC, Yoshida S, Herrera-Imbroda B, Gratton M, Gschwend JE, Hope TA, Joensuu H, Kuss I, Le Berre MA, Dimova-Dobreva M, Fizazi K

Future Oncol. 2025 11 11;:1-8

Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.

Reverdy T, Izarn F, Allignet B, Roubaud G, Gibson N, Teyssonneau D, Thibault C, Berthou H, Houede N, Fléchon A, Tartas S, Moinard-Butot F, Barthelemy P, Maillet D

Clin Genitourin Cancer. 2025 11 11;24(1):102465

Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.

Flippot R, Vano YA, Dalban C, Beuselinck B, Fléchon A, Meylan M, Pouessel D, Bougoüin A, Sautes-Fridman C, Gravis G, Chaput N, Oudard S, Desnoyer A, Laguerre B, Chouaib S, Barthelemy P, Borchiellini D, Carril-Ajuria L, Gross-Goupil M, Fridman WH, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Chabaud S, Escudier B, Rioux-Leclercq N, Albiges L,

Eur Urol. 2025 11 11;:

Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.

Fizazi K, de Bono JS, Laird AD, Barthélémy P, Delva R, Dorff T, Maruzzo M, Stirling A, Machiels JP, Dumez H, Renard V, Hopkins JF, Albacker LA, Chen HC, Healy CG, DeAnnuntis L, Chelliserry J, van Oort IM, Scagliotti GV, Mehra N

Eur Urol Oncol. 2025 10 30;:

Updated 2025 French Guidelines for Renal Cell Carcinoma.

Bigot P, Khene ZE, Boissier R, Albiges L, Bernhard JC, Chapet O, Correas JM, Vergie S, Doumerc N, Ferragu M, Ingels A, Margue G, Neuzillet Y, Ouzaïd I, Pettenati C, Rioux-Leclercq N, Waeckel T, Barthelemy P, Roupret M

Fr J Urol. 2025 10 16;:103007

Guiding First-Line Treatment Decisions In Advanced Urothelial Carcinoma: A Global Survey.

Grande E, Bellmunt J, Hussain SA, Al Mansour MM, Bamias A, Barthélémy P, Benjamin DJ, Blais N, Bourlon MT, Castellano D, Danchaivijitr P, Fernandez Lazzaro M, Giannatempo P, Guerrero-Ramos F, Iacovelli R, Ivanyi P, Jung EH, Kanesvaran R, Manneh R, Marinho JC, Matsubara N, Merseburger AS, Mukherji D, Park CH, Tran B, da Trindade KM, Ürün Y, Kamat AM, Birtle AJ

Oncologist. 2025 10 6;:

Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study.

Barthelemy P, Thiery-Vuillemin A, Lebret T, Bigot P, Stein U, Dourthe LM, Longo R, Gimel P, Auberger B, De La Cruz J, Malak D, Samia Z, Texier N, Albiges L

ESMO Real World Data Digit Oncol. 2025 09;9:100155

Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC.

Fritzsch A, Leucht K, Röber N, Conrad K, Rothe R, Wehner R, Schumacher U, Esteban E, Barthélémy P, Schmidinger M, Schmitz M, Grimm MO

ESMO Open. 2025 08 28;10(9):105575

First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.

Voss MH, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthélémy P, Lee JL, Nalbandian T, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Cornell J, Sharma M, Burgents JE, Albiges L

Eur Urol. 2025 07 23;:

Impact of gastrectomy on cabozantinib exposure: Clinical case of a patient with clear renal cell carcinoma.

Kdadri S, Moinard-Butot F, Schmitt A, Royer B, Barthélémy P

Clin Genitourin Cancer. 2025 07 7;23(5):102396

Beyond the Scalpel: the Role of Image-Guided Thermal Ablation in Management of Metastatic Renal Cell Carcinoma in the Era of Immunotherapy.

Fung KFK, Barthelemy P, Moinard-Butot F, Airoldi M, Cazzato RL, Gangi A

Cardiovasc Intervent Radiol. 2025 06 24;:

Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study.

Grünwald V, Bex A, Rottey S, Suárez C, Procopio G, Velasco G, Melichar B, Bedke J, Pickering L, Fontes-Sousa M, Schmidinger M, Bamias A, Gross-Goupil M, Porta C, Barthélémy P, Escudier B, Albiges L

Eur J Cancer. 2025 06 7;225:115569

rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.

Chi KN, McKay RR, Sandhu S, Arranz JA, Barthélémy P, Hadaschik B, Matsubara N, Shore ND, Ye D, Cascella T, Irincheeva I, Kreiser S, Thiery-Vuillemin A, Rathkopf DE

Future Oncol. 2025 06 2;:1-7

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Blanc J, Carnot A, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaudenarde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N

J Immunother Cancer. 2025 05 24;13(5):

Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial.

Saint-Ghislain M, Chabaud S, Dalenc F, Allouache D, Cameron D, Martinez M, Grenier J, Barthelemy P, Brunt M, Kaluzinski L, Mailliez A, Legouffe E, Hardy-Bessard AC, Giacchetti S, Mouret-Reynier MA, Canon JL, Bliss J, Lemonnier J, Andre F, Bachelot T, Cottu P

ESMO Open. 2025 04 15;10(5):105050

Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis.

Barthélémy P, Musat MG, Moradian H, Kearney M

Future Oncol. 2025 04 4;:1-12

Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients.

Annakib S, Di Méglio E, Dibert-Bekoy Y, Chevallier T, Roubaud G, Fournel P, Guillot A, Borchiellini D, Pouessel D, Boughalem E, Delva R, Barthelemy P, Oudard S, Thibault C, Tosi D, Houédé N, Fiteni F

Cancer Med. 2025 04;14(8):e70896

Prospective Randomised Phase-II Trial of Ipilimumab/Nivolumab versus Standard of Care in non-clear cell Renal Cell Cancer - Results of the SUNNIFORECAST Trial.

Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suarez C, Maroto P, Grünwald V, Oosting SF, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Haanen JB,

Ann Oncol. 2025 04 1;:

[How to optimize the management of patients with locally advanced and/or metastatic urothelial cancers?].

Houédé N, Barthelemy P, Gobert A, Pradere B, Pignot G

Bull Cancer. 2025 04 1;:

Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT).

Gavira J, Auclin E, Rey-Cardenas M, Roy P, Tapia JC, Nay P, Vinceneux A, Lefort F, Nannini S, Randis AMDC, Naoun N, Escudier B, Borchiellini D, de Velasco G, Barthelemy P, Gross-Goupil M, Negrier S, Oudard S, Frazer RD, Albiges L, Flippot R

Eur J Cancer. 2025 03 26;220:115389

Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer.

Poterszman N, Hammer-Lefevre C, Porot C, Salvadori J, Barthélémy P, Somme F

Theranostics. 2025 03 3;15(9):3724-3732

Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians.

Grande E, Hussain SA, Barthélémy P, Kanesvaran R, Giannatempo P, Benjamin DJ, Hoffman J, Birtle A

Cancer Treat Rev. 2025 02 10;134:102900

Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study.

Albiges L, Gross-Goupil M, Barthélémy P, Bamias A, Bedke J, Bex A, Fontes-Sousa M, Grünwald V, Melichar B, Pickering L, Porta C, Procopio G, Rottey S, Schmidinger M, Suárez C, Velasco G, Escudier B

Eur Urol Oncol. 2025 02 8;:

Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.

Satoh T, Barthélémy P, Nogova L, Honda K, Hirano H, Lee KW, Rha SY, Ryu MH, Park JO, Doi T, Ajani J, Hangai N, Kremer J, Mina M, Liu M, Shitara K

Eur J Cancer. 2025 01 27;218:115262

Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128).

Moinard-Butot F, Thouvenin J, Bigot P, Martinez-Chanza N, Gaillard V, Cazzato RL, Boissier R, Margue G, Boudier P, Maillet D, Gross-Goupil M, Bernhard JC, Barthélémy P

World J Urol. 2025 01 10;43(1):66

The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma.

Pignot G, Margue G, Bigot P, Lang H, Balssa L, Roubaud G, Borchiellini D, Bensalah K, Schlürmann F, Ladoire S, Parier B, Bernhard JC, Cassuto O, Albigès L, Thibault C, Ingels A, Cherifi F, Waeckel T, Flippot R, Geoffrois L, Walz J, Gravis G, Barthélémy P

World J Urol. 2025 01 2;43(1):54

Central nervous system complications of immune checkpoint inhibitors: a comprehensive review.

Lopes S, Pabst L, Bahougne T, Barthelemy P, Guitton R, Didier K, Geoffrois L, Granel-Brocard F, Mennecier B, Mascaux C, Kremer S, Collongues N

Crit Rev Oncol Hematol. 2024 12 12;:104595

Sex Disparities in Bladder Cancer Diagnosis and Treatment.

Pignot G, Barthélémy P, Borchiellini D

Cancers (Basel). 2024 12 7;16(23):

A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE).

Staehler M, Basso U, Eymard JC, Barthelemy P, Bigot P, Laramas M, Rink M, Suarez C, Guillot A, Bedke J, Hamberg P, De Vivo R, Gajate P, Lázaro-Quintela M, Rastogi P, Perrot V, Qvick B, Dutailly P, Verzoni E, Procopio G

Clin Genitourin Cancer. 2024 11 30;23(1):102285

Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n°157).

Margue G, Klein C, Parier B, Albiges L, Pignot G, Gravis G, Bigot P, Baize N, Ingels A, Joly C, Audenet F, Vano Y, Waeckel T, Levard R, Barthelemy P, Ambrosetti D, Verkarre V, Yacoub M, Gross-Goupil M, Bernhard JC

Urol Oncol. 2024 11 26;:

French AFU Cancer Committee Guidelines - Update 2024-2026: Management of kidney cancer.

Bigot P, Boissier R, Khene ZE, Albigès L, Bernhard JC, Correas JM, De Vergie S, Doumerc N, Ferragu M, Ingels A, Margue G, Ouzaïd I, Pettenati C, Rioux-Leclercq N, Sargos P, Waeckel T, Barthelemy P, Rouprêt M

Fr J Urol. 2024 11;34(12):102735

Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment.

Barthélémy P, Thibault C, Fléchon A, Gross-Goupil M, Voog E, Eymard JC, Abraham C, Chasseray M, Lorgis V, Hilgers W, Gobert A, Le Moulec S, Simon C, Nicolas E, Escande A, Pouessel D, Mouillet G, Josse C, Solbes MN, Lambert P, Loriot Y

Eur Urol Oncol. 2024 10 23;:

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, Gross-Goupil M, Schinzari G, Melichar B, Barthélémy P, Ruiz Garcia A, Sosman J, Grimm MO, Goh JC, Suarez C, Kollmannsberger CK, Nair SG, Shuch BM, Huang J, Simsek B, Spiridigliozzi J, Lee CW, van Kooten Losio M, Grünwald V

J Clin Oncol. 2024 09 20;:JCO2400773

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.

Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ

Lancet. 2024 09 12;:

Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial.

Oudard S, Tran Y, Helissey C, Vauchier C, Ratta R, Bennamoun M, Voog E, Hasbini A, Thiery-Vuillemin A, Aldabbagh K, Saldana C, Sevin E, Amela E, Von Amsberg G, Houede N, Besson D, Feyerabend S, Boegemann M, Pfister D, Schostak M, Huillard O, Di Fiore F, Quivy A, Vernerey D, Falcoz A, Youcef-Ali K, Kotti S, Lepicard EM, Barthelemy P

Eur Urol Oncol. 2024 08 13;:

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.

Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, Jiang R, Desilva H, Federov V, Lee CW, Motzer RJ

Ann Oncol. 2024 08 2;:

Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer.

Loriot Y, Balar AV, Petrylak DP, Kalebasty AR, Grivas P, Fléchon A, Jain RK, Swami U, Bupathi M, Barthélémy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zavodovskaya M, Elboudwarej E, Diehl L, Jürgensmeier JM, Tagawa ST

Clin Cancer Res. 2024 08 1;30(15):3179-3188

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study.

Barthélémy P, Albigès L, Escudier B, Narciso B, Bigot P, Chehimi M, Emambux S, Calcagno F, Mouillet G, Eymard JC, Schlürmann F, Bailly S, Garbay D, Berdah JF, Palmaro MB, Goupil MG, Spaeth D, Néré S, Quentric C, Vano YA, Thiery-Vuillemin A

ESMO Open. 2024 06 18;9(7):103602

Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate of Patients With Metastatic Renal Cell Carcinomas.

Moinard-Butot F, Oriel M, Tricard T, Cazzato RL, Pierard L, Gaillard V, Werle P, Lindner V, Martin S, Schuster C, Roy C, Burgy M, Anthony A, Bigot C, Boudier P, Fritsch A, Olland A, Malouf G, Lang H, Barthélémy P

Clin Genitourin Cancer. 2024 06 5;22(5):102134

Biomarqueurs émergents dans les cancers du rein à cellules claires.

Barthélémy P

Bull Cancer. 2024 06;111(6S1):6S7-6S9

Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review.

Baboudjian M, Peyrottes A, Dariane C, Fromont G, Denis JA, Fiard G, Kassab D, Ladoire S, Lehmann-Che J, Ploussard G, Rouprêt M, Barthélémy P, Roubaud G, Lamy PJ

Eur Urol Oncol. 2024 05 31;:

Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: a review on behalf of the CC AFU.

Bentahila R, Bensalah K, Benziane-Ouaritini N, Barthelemy P, Rioux-Leclerc N, Correas JM, Belhomme S, Bigot P, Sargos P

Fr J Urol. 2024 05 30;:102660

Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.

Penault-Llorca F, Dalenc F, Chabaud S, Cottu P, Allouache D, Cameron D, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Debled M, Hardy-Bessard AC, Giacchetti S, Barthelemy P, Kaluzinski L, Mailliez A, Mouret-Reynier MA, Legouffe E, Cayre A, Martinez M, Delbaldo C, Mollon-Grange D, Macaskill EJ, Sephton M, Stefani L, Belgadi B, Winter M, Orfeuvre H, Lacroix-Triki M, Bonnefoi H, Bliss J, Canon JL, Lemonnier J, Andre F, Bachelot T

ESMO Open. 2024 04 30;9(5):103443

A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.

Loriot Y, Kalebasty AR, Fléchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Bangs R, Tagawa ST

Future Oncol. 2024 04 29;:

Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.

Carril-Ajuria L, Lavaud P, Dalban C, Negrier S, Gravis G, Motzer RJ, Chevreau C, Tannir NM, Oudard S, McDermott DF, Laguerre B, Hammers HJ, Barthelemy P, Plimack ER, Borchiellini D, Gross-Goupil M, Jiang R, Lee CW, de Silva H, Rini BI, Escudier B, Albigès L

Eur J Cancer. 2024 04 8;204:114048

Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.

Mourey L, Rainho LT, Dalban C, Carril-Ajuria L, Negrier S, Chevreau C, Gravis G, Thibault C, Laguerre B, Barthelemy P, Borchiellini D, Gross-Goupil M, Geoffrois L, Rolland F, Thiery-Vuillemin A, Tantot F, Chaput N, Naigeon M, Teixeira M, Escudier B, Flippot R, Albiges L

Eur J Cancer. 2024 02 3;201:113589

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.

Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, Agarwal N, Gupta S, Fléchon A, Ramamurthy C, Davis NB, Recio-Boiles A, Sternberg CN, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa ST, Loriot Y

J Clin Oncol. 2024 01 23;:JCO2202835

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

Loriot Y, Petrylak DP, Kalebasty AR, Fléchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Tagawa ST

Ann Oncol. 2024 01 18;:

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study.

Carneiro F, Vinceneux A, Larroquette M, Rony M, Carril L, Laguerre B, Blazevic I, Bartelemy P, Teyssonneau D, Goujon M, Linassier C, Thiery-Vuillemin A, Roubaud G, Mourey L, Albiges L, Gravis G, Gross-Goupil M, Cancel M

Eur J Cancer. 2024 01 15;199:113534

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.

Fizazi K, Bernard-Tessier A, Roubaud G, Utriainen T, Barthélémy P, Fléchon A, van der Voet J, Gravis G, Ratta R, Jones R, Parikh O, Tanner M, Antonarakis ES, Baldini C, Peters N, Garratt C, Ikonen T, Pohjanjousi P, Joensuu H, Cook N

NEJM Evid. 2024 01;3(1):EVIDoa2300171

Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.

Lu X, Vano YA, Su X, Helleux A, Lindner V, Mouawad R, Spano JP, Rouprêt M, Compérat E, Verkarre V, Sun CM, Bennamoun M, Lang H, Barthelemy P, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG

Cell Rep Med. 2023 11 8;:101287

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, Kristanto P, Eiger D, Goncalves A, Ghiringhelli F, Taylor D, Clatot F, Van den Mooter T, Ferrero JM, Bonnefoi H, Canon JL, Duhoux FP, Mansi L, Poncin R, Barthélémy P, Isambert N, Denis Z, Catteau X, Salgado R, Agostinetto E, de Azambuja E, Rothé F, Craciun L, Venet D, Romano E, Stagg J, Paesmans M, Larsimont D, Sotiriou C, Ignatiadis M, Piccart-Gebhart M

Nat Commun. 2023 11 2;14(1):7018

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.

Oudard S, Ratta R, Voog E, Barthelemy P, Thiery-Vuillemin A, Bennamoun M, Hasbini A, Aldabbagh K, Saldana C, Sevin E, Amela E, Von Amsberg G, Houede N, Besson D, Feyerabend S, Boegemann M, Pfister D, Schostak M, Huillard O, Di Fiore F, Quivy A, Lange C, Phan L, Belhouari H, Tran Y, Kotti S, Helissey C

JAMA Oncol. 2023 10 26;:

BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors.

Martins-Branco D, Nader-Marta G, Gombos A, Barthelemy P, Goncalves A, Borcoman E, Clatot F, Holbrechts S, De Maio D'Esposito E, Cheymol C, Vanhaudenarde V, Duhoux FP, Duhem C, Decoster L, Denys H, Lefranc F, Canon JL, Clement PM, Gligorov J, Paesmans M, Kindt N, Awada A, Kotecki N

Nat Med. 2023 10 19;:

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.

Grimm MO, Esteban E, Barthélémy P, Schmidinger M, Busch J, Valderrama BP, Charnley N, Schmitz M, Schumacher U, Leucht K, Foller S, Baretton G, Duran I, de Velasco G, Priou F, Maroto P, Albiges L,

Lancet Oncol. 2023 10 13;:

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.

Grivas P, Grande E, Davis ID, Moon HH, Grimm MO, Gupta S, Barthélémy P, Thibault C, Guenther S, Hanson S, Sternberg CN

ESMO Open. 2023 10 12;8(6):102050

Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.

Billon E, Dalban C, Oudard S, Chevreau C, Laguerre B, Barthélémy P, Borchiellini D, Geoffrois L, Negrier S, Joly F, Thiery-Vuillemin A, Gross-Goupil M, Rolland F, Priou F, Mahammedi H, Tantot F, Escudier B, Chabaud S, Albiges L, Gravis G

Eur Urol Oncol. 2023 10 7;:

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.

Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthélémy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albigès L, George S, Shuch B, Sosman J, Staehler M, Vázquez Estévez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A

Target Oncol. 2023 09 2;:

Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.

Baudry E, Naoun N, Auclin E, Saldana C, Barthelemy P, Geoffrois L, Thibault C, de Vries-Brilland M, Borchiellini D, Maillet D, Hirsch L, Vauchier C, Carril-Ajuria L, Colomba E, Bernard-Tessier A, Escudier B, Flippot R, Albigès L

Eur J Cancer. 2023 08 18;193:113292

Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.

Guilhem-Ducléon G, Dalban C, Negrier S, Gravis G, Laguerre B, Chevreau C, Oudard S, Barthelemy P, Ladoire S, Boughalem E, Borchiellini D, Linassier C, Nenan S, Flippot R, Albiges L, Goupil MG

Clin Genitourin Cancer. 2023 07 20;:

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.

Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Perini RF, Sharma M, Peng X, Lee CH

Lancet Oncol. 2023 07 11;:

CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.

Barthélémy P, Dutailly P, Qvick B, Perrot V, Verzoni E

Future Oncol. 2023 07 5;:

Mesenchymal-like tumor cells and myofibroblastic cancer-associated fibroblasts are associated with progression and immunotherapy response of clear-cell renal cell carcinoma.

Davidson G, Helleux A, Vano YA, Lindner V, Fattori A, Cerciat M, Elaidi RT, Verkarre V, Sun CM, Chevreau C, Bennamoun M, Lang H, Tricard T, Fridman WH, Sautes-Fridman C, Su X, Plassard D, Keime C, Thibault-Carpentier C, Barthélémy P, Oudard SM, Davidson I, Malouf GG

Cancer Res. 2023 06 19;:

Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma.

Masson C, Thouvenin J, Boudier P, Maillet D, Kuchler-Bopp S, Barthélémy P, Massfelder T

Cancers (Basel). 2023 06 12;15(12):

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.

Colomba E, Jonas SF, Eymard JC, Delva R, Brachet PE, Neuzillet Y, Penel N, Roubaud G, Bompas E, Mahammedi H, Longo R, Helissey C, Barthélemy P, Borchiellini D, Hasbini A, Priou F, Saldana C, Voog E, Narcisso B, Ladoire S, Berdah JF, Aisenfarb JB, Foulon S, Fizazi K

Eur Urol. 2023 06 2;:

[New European approval: Fixed dose association of niraparib and abiraterone acetate in metastatic castration resistant prostate cancer with BRCA1/2 mutation].

Bischoff H, Barthélémy P

Bull Cancer. 2023 05 12;:

Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).

Thibault C, Fléchon A, Albiges L, Joly C, Barthelemy P, Gross-Goupil M, Chevreau C, Coquan E, Rolland F, Laguerre B, Gravis G, Pécuchet N, Elaidi RT, Timsit MO, Brihoum M, Auclin E, de Reyniès A, Allory Y, Oudard S

Eur J Cancer. 2023 03 23;186:83-90

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.

Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthélémy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albigès L, George S, Shuch B, Sosman J, Staehler M, Vázquez Estévez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A

Lancet. 2023 02 9;:

Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients' Outcomes?

Thouvenin J, Masson C, Boudier P, Maillet D, Kuchler-Bopp S, Barthélémy P, Massfelder T

Cancers (Basel). 2023 01 27;15(3):

Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.

Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-Vuillemin A, Berdah JF, Ferrari V, Dominique Thomas Q, Mione C, Curcio H, Oudard S, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C

Eur J Cancer. 2023 01 13;182:66-76

Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.

Carril-Ajuria L, Colomba E, Romero-Ferreiro C, Cerbone L, Ratta R, Barthelemy P, Vindry C, Fléchon A, Cherifi F, Boughalem E, Linassier C, Fornarini G, Rebuzzi SE, Gross-Goupil M, Saldana C, Martin-Soberón M, de Velasco G, Manneh R, Pernaut C, Sanchez de Torre A, Flippot R, Escudier B, Albiges L

Eur J Cancer. 2022 11 26;180:21-29

French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer.

Bigot P, Barthelemy P, Boissier R, Khene ZE, Pettenati C, Bernhard JC, Correas JM, Doumerc N, Gimel P, Ingels A, Nouhaud FX, Ouzaïd I, Rioux-Leclercq N, Albiges L, Rouprêt M

Prog Urol. 2022 11;32(15):1195-1274

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.

Mehra N, Fizazi K, de Bono JS, Barthélémy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV

Oncologist. 2022 09 19;:

Genomics to select treatment for patients with metastatic breast cancer.

Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin MP, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero JM, Emile G, Mouret-Reynier MA, Thery JC, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T, Bieche I

Nature. 2022 09 7;:

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.

Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG

Oncologist. 2022 08 18;:

Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.

Pignot G, Thiery-Vuillemin A, Albigès L, Walz J, Lang H, Balssa L, Parier B, Geoffrois L, Bensalah K, Schlürmann F, Ladoire S, Bigot P, Borchiellini D, Cassuto O, Thibault C, Ingels A, Saldana V, Roubaud G, Bernhard JC, Gravis G, Barthélémy P

Eur Urol Oncol. 2022 07 16;:

Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Rassy E, Dalban C, Colomba E, Derosa L, Alves Costa Silva C, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L

Clin Genitourin Cancer. 2022 07 10;:

Does the Time to Start First-Line Treatment Influence the Survival of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma? Results of the MetaSurv-UroCCR 79 Study.

Rolley C, Barthelemy P, Bensalah K, Nouhaud FX, Villers A, Bruyère F, Lebdai S, Ricard S, Gross-Goupil M, Rouprêt M, Bernhard JC, Bigot P

Clin Genitourin Cancer. 2022 07 9;:

Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.

Saad F, de Bono J, Barthélémy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano CS, Gurney H, Healy C, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K

Eur Urol. 2022 06 21;:

The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Loriot Y, Texier M, Culine S, Fléchon A, Thiery-Vuillemin A, Gravis G, Geoffrois L, Chevreau C, Gross-Goupil M, Barthelemy P, Bompas E, Mahammedi H, Laguerre B, Lacourtoisie SA, Helissey C, Ladoire S, Abraham C, Massard C, Grimaldi S, Fizazi K

Eur Urol. 2022 05 19;:

Advanced nccRCC: what therapeutic options in 2022?

Bigot C, Boudier P, Ladoire S, Barthélémy P

Bull Cancer. 2022 05;109(2S):2S39-2S46

Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.

Gaillard V, Lhuillier A, Bigot C, Pierard L, Trensz P, Burgy M, Schuster C, Malouf G, Fritsch A, Lang H, Tricard T, Borchiellini D, Geoffrois L, Barthelemy P

Support Care Cancer. 2022 Apr 29;:

Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.

Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Powles T, Donskov F, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, McHenry MB, Lee CW, McCarthy J, Ejzykowicz F, Tannir NM

Cancer. 2022 Apr 5;:

Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.

Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S

Lancet Oncol. 2022 Apr 4;:

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study.

Guillaume Z, Colomba E, Thouvenin J, Saldana C, Campedel L, Dumont C, Laguerre B, Maillet D, Vicier C, Rolland F, Borchiellini D, Barthelemy P, Albiges L, Auclin E, Roulleaux Dugage M, Oudard S, Thibault C

Cancers (Basel). 2022 Mar 25;14(7):

Percutaneous Image-Guided Cryoablation of Post-Surgical Renal Cancer Recurrences in the Renal Fossa: A Single-Center Retrospective Analysis.

Bertucci G, Cazzato RL, Barthelemy P, Dalili D, Lang H, Garnon J, Gangi A

Cardiovasc Intervent Radiol. 2022 Jan 3;:

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.

Vauchier C, Auclin E, Barthélémy P, Carril-Ajuria L, Ryckewaert T, Borchiellini D, Castel-Ajgal Z, Bennamoun M, Campedel L, Thiery-Vuillemin A, Coquan E, Crouzet L, Berdah JF, Chevreau C, Ratta R, Fléchon A, Lefort F, Albiges L, Gross-Goupil M, Vano YA, Thibault C, Oudard S

J Oncol. 2022 ;2022:3449660

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.

Oudard S, Benhamouda N, Escudier B, Ravel P, Tran T, Levionnois E, Negrier S, Barthelemy P, Berdah JF, Gross-Goupil M, Sternberg CN, Bono P, Porta C, Giorgi U, Parikh O, Hawkins R, Highley M, Wilke J, Decker T, Tanchot C, Gey A, Terme M, Tartour E

Cells. 2021 Dec 22;11(1):

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).

Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A

BMC Cancer. 2021 Dec 2;21(1):1292

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.

Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, Bompas E, Joly F, Greilsamer C, Hon TNT, Barthelemy P, Culine S, Berdah JF, Deblock M, Ratta R, Flechon A, Cheneau C, Maillard A, Martineau G, Borget I, Fizazi K,

Eur Urol. 2021 Nov 14;:

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.

Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Leung D, Saggi SS, Lee CW, McHenry MB, Motzer RJ

Eur Urol. 2021 Nov 5;:

Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.

Aldea M, Lam L, Orillard E, Llacer Perez C, Saint-Ghislain M, Gravis G, Fléchon A, Roubaud G, Barthelemy P, Ricci F, Priou F, Neviere Z, Beaufils M, Laguerre B, Hardy AC, Helissey C, Ratta R, Borchiellini D, Pobel C, Joly F, Castro E, Thiery-Vuillemin A, Baciarello G, Fizazi K

Eur J Cancer. 2021 Nov 2;159:87-97

External Validation of the ASSURE Model for Predicting Oncological Outcomes After Resection of High-risk Renal Cell Carcinoma (RESCUE Study: UroCCR 88).

Khene ZE, Larcher A, Bernhard JC, Doumerc N, Ouzaid I, Capitanio U, Nouhaud FX, Boissier R, Rioux-Leclercq N, De La Taille A, Barthelemy P, Montorsi F, Rouprêt M, Bigot P, Bensalah K,

Eur Urol Open Sci. 2021 Nov;33:89-93

Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy.

Sebbag E, Psimaras D, Baloglu S, Bourgmayer A, Moinard-Butot F, Barthélémy P, Tranchant C, Honnorat J, Bender L

J Neuroimmune Pharmacol. 2021 Oct 22;:

Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.

Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK

JAMA Oncol. 2021 Oct 21;:

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).

Cancel M, Fromont G, Blonz C, Chevreau C, Rioux-Leclercq N, Laguerre B, Oudard S, Gross-Goupil M, Gravis G, Goldwasser F, Rolland F, Delva R, Moise L, Emambux S, Vassal C, Zanetta S, Penel N, Fléchon A, Barthélémy P, Saldana C, Lefort F, Escudier B, Linassier C, Albiges L

Eur J Cancer. 2021 Oct 4;158:1-11

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

Culine S, Harter V, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Abadie-Lacourtoisie S, Geoffrois L, Fiore FD, Roubaud G, Barthélémy P, Voog E, Emambux S, Serrate C, Saldana C, Nguyen-Tan-Hon T, Loriot Y, Eymard JC, Huillard O, Rolland F, Houédé N, Spano JP, Demery ME, Vieillot S, L'Haridon T, Hilgers W, Allory Y, Pfister C,

Clin Genitourin Cancer. 2021 Sep 8;:

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions.

Thouvenin J, Martínez Chanzá N, Alhalabi O, Lang H, Tannir NM, Barthélémy P, Malouf GG

Cancers (Basel). 2021 Aug 27;13(17):

Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.

Pobel C, Auclin E, Teyssonneau D, Laguerre B, Cancel M, Boughalem E, Noel J, Brachet PE, Maillet D, Barthelemy P, Helissey C, Thibault C, Oudard S

Cancer Med. 2021 Aug 12;:

Nanoaggregate-forming lipid-conjugated AS1411 aptamer AS a promising tumor-targeted delivery system of anticancer agents in vitro.

Carvalho J, Lopes-Nunes J, Vialet B, Rosado T, Gallardo E, Vale J, Eloy C, Ferreira S, Palmeira-de-Oliveira R, Campello MPC, Paulo A, Barthélémy P, Mergny JL, Salgado GF, Queiroz JA, Ellington AD, Cruz C

Nanomedicine. 2021 Jun 23;:102429

The NHance Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.

Aftimos P, Rolfo C, Rottey S, Barthélémy P, Borg C, Park K, Oh DY, Kim SW, De Jonge N, Hanssens V, Zwanenpoel K, Molthoff C, Vugts D, Dreier T, Verheesen P, van Dongen GAMS, Jacobs J, Van Rompaey L, Hultberg A, Michieli P, Pauwels P, Fung S, Thibault A, de Haard H, Leupin N, Awada A

Biomedicines. 2021 Jun 10;9(6):

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.

Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, T'Kint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ

Prostate Cancer Prostatic Dis. 2021 Jun 9;:

Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.

Courcier J, Dalban C, Laguerre B, Ladoire S, Barthélémy P, Oudard S, Joly F, Gravis G, Chevreau C, Geoffrois L, Deluche É, Rolland F, Topart D, Culine S, Négrier S, Mahammedi H, Tantot F, Jamet A, Escudier B, Flippot R, Albigès L

Eur Urol. 2021 Jun 5;:

COVID-19 in cancer patients: A retrospective study of 212 cases from a French SARS-CoV-2 cluster during the first wave of the COVID-19 pandemic.

Martin S, Kaeuffer C, Leyendecker P, Tuzin N, Tazi Y, Schaff-Wendling F, Kleinheny T, Husson-Wetzel S, Pamart G, Limacher JM, Clerc O, Dicop E, Kurtz JE, Barthélémy P, Gantzer J

Oncologist. 2021 May 24;:

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.

Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P

J Clin Oncol. 2021 Apr 30;:JCO2003489

Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.

Barthélémy P, Rioux-Leclercq N, Thibault C, Saldana C, Borchiellini D, Chevreau C, Desmoulins I, Gobert A, Hilgers W, Khalil A, Lemoine N, Schlürmann-Constans F, Négrier S

Cancer Treat Rev. 2021 Apr 9;97:102191

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.

Culine S, Fléchon A, Gravis G, Roubaud G, Loriot Y, Joly F, Barthélémy P, Assaf E, Mahammedi H, Beuzeboc P, Houédé N, Rolland F, Guillot A, Gross-Goupil M, Spano JP, Tartas S, Deblock M, Chevreau C, Serrate C, Manduzio H, Habibian M, Thézénas S, Allory Y

Clin Genitourin Cancer. 2021 Feb 24;:

Cabozantinib: a new first-line option for papillary renal cell carcinoma?

Borchiellini D, Barthélémy P

Lancet. 2021 Feb 12;:

Intravenous and subcutaneous administration of trastuzumab in a patient on peritoneal dialysis.

Kokkali S, Ternant D, Kemmel V, Levêque D, Wendling F, Barthelemy P, Kurtz JE

Br J Clin Pharmacol. 2021 Jan 19;:

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.

Bachelot T, Filleron T, Bieche I, Arnedos M, Campone M, Dalenc F, Coussy F, Sablin MP, Debled M, Lefeuvre-Plesse C, Goncalves A, Reynier MM, Jacot W, You B, Barthelemy P, Verret B, Isambert N, Tchiknavorian X, Levy C, Thery JC, L'Haridon T, Ferrero JM, Mege A, Del Piano F, Rouleau E, Tran-Dien A, Adam J, Lusque A, Jimenez M, Jacquet A, Garberis I, Andre F

Nat Med. 2021 Jan 18;:

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X

PLoS One. 2021 ;16(9):e0248222

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.

Albiges L, Fléchon A, Chevreau C, Topart D, Gravis G, Oudard S, Tourani JM, Geoffrois L, Meriaux E, Thiery-Vuillemin A, Barthélémy P, Ladoire S, Laguerre B, Perrot V, Billard A, Escudier B, Gross-Goupil M

Eur J Cancer. 2020 Nov 27;142:102-111

Albiges L, Tannir N, Burotto M, Mcdermott D, Plimack E, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger C, Gurney H, Grimm M, Tomita Y, Castellano D, Rini B, Choueiri T, Shally Saggi S, Mchenry M, Motzer R

Prog Urol. 2020 Nov;30(13):785-786

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Saggi SS, McHenry MB, Motzer RJ

ESMO Open. 2020 Nov;5(6):

TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients with Metastatic Renal Cell Carcinoma.

Albiges L, Barthélémy P, Gross-Goupil M, Negrier S, Needle MN, Escudier B

. 2020 Sep 30;:

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.

Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC, Ficial M, Arén Frontera O, George S, Donskov F, Harrison MR, Powles T, Barthélémy P, Tykodi SS, Kocsis J, Ravaud A, Rodriguez-Cid JR, Pal SK, Murad AM, Ishii Y, Saggi SS, McHenry MB, Rini BI

Clin. Cancer Res.. 2020 Sep 1;:

Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.

de Vries-Brilland M, Gross-Goupil M, Seegers V, Boughalem E, Beuselinck B, Thibault C, Chevreau C, Ladoire S, Barthélémy P, Negrier S, Borchiellini D, Huillard O, Geoffrois L, Gravis G, Saldana C, Thiery-Vuillemin A, Escudier B, Ravaud A, Albiges L

Eur. J. Cancer. 2020 Jul 9;136:76-83

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.

Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER, Barthélémy P, Hammers HJ, George S, Grünwald V, Porta C, Neiman V, Ravaud A, Choueiri TK, Rini BI, Salman P, Kollmannsberger CK, Tykodi SS, Grimm MO, Gurney H, Leibowitz-Amit R, Geertsen PF, Amin A, Tomita Y, McHenry MB, Saggi SS, Tannir NM

J Immunother Cancer. 2020 Jul;8(2):

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.

Elaidi R, Phan L, Borchiellini D, Barthelemy P, Ravaud A, Oudard S, Vano Y

Cancers (Basel). 2020 Jun 24;12(6):

Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.

Simonaggio A, Elaidi R, Fournier L, Fabre E, Ferrari V, Borchiellini D, Thouvenin J, Barthelemy P, Thibault C, Tartour E, Oudard S, Vano YA

Cancer Immunol. Immunother.. 2020 Jun 19;:

French Multidisciplinary Approach for the Treatment of MSK Tumors.

Cazzato RL, Garnon J, De Marini P, Auloge P, Dalili D, Koch G, Antoni D, Barthelemy P, Kurtz JE, Malouf G, Feydy A, Charles YP, Gangi A

Semin Musculoskelet Radiol. 2020 Jun;24(3):310-322

[Non-clear cell renal cell carcinoma: clinico-biological characteristics and therapeutic management except surgery].

Thouvenin J, Barthélémy P, Ladoire S

Bull Cancer. 2020 Jun;107(5S):S56-S65

[MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].

Herrscher H, Boilève A, Lindner V, Barthélémy P, Hutt É, Pierard L, Kurtz JE, Rioux-Leclercq N, Lang H, Malouf GG

Bull Cancer. 2020 Feb 7;:

Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?

Pignot G, Thiery-Vuillemin A, Walz J, Lang H, Werle P, Balssa L, Geoffrois L, Leblanc L, Albigès L, di Nunno V, Bensalah K, Ladoire S, Gravis G, Barthélémy P

Eur. Urol.. 2020 Jan 3;:

Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities.

Debien V, Thouvenin J, Lindner V, Barthélémy P, Lang H, Flippot R, Malouf GG

Cancers (Basel). 2019 Dec 31;12(1):

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

Sroussi M, Elaidi R, Fléchon A, Lorcet M, Borchiellini D, Tardy MP, Gravis G, Guérin M, Laguerre B, Estrade F, Delva R, Barthélémy P, Loriot Y, Lavaud P, Lebret T, Neuzillet Y, Penel N, Houede N, Pouessel D, Rousseau B, Mussat E, Gross-Goupil M, Culine S, Gauthier H, Gobert A, Roupret M, Huillard O, Tartas S, Radulescu C, Allory Y, Oudard S

Clin Genitourin Cancer. 2019 Dec 5;:

Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.

Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthélémy P, Sella A, Fizazi K, Ferrero JM, Laguerre B, Thibault C, Hans S, Oudard S

Eur. J. Cancer. 2019 Nov 28;:

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM,

Lancet Oncol.. 2019 Aug 16;:

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L

J. Clin. Oncol.. 2019 Jun 13;:JCO1802218

Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies.

El Ali Z, Rottey S, Barthelemy P, Kotecki N, VAN Paemel R, Devrient D, Awada A, Gil T, Pannier D, Ryckewaert T, Waisse W, Clavier JB, Penel N, Vermassen T

Anticancer Res.. 2019 Jun;39(6):2993-3002

Hidden intra-mandibular carcinoma cuniculatum appearing in a patient with metastatic prostate cancer: a case report.

Broly E, Barthélémy P, Ciftci S, Borel C, Broly M, Gros CI, Marcellin L, Bornert F

BMC Oral Health. 2019 Apr 5;19(1):54

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L

Eur. J. Cancer. 2019 Jan 4;108:33-40

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.

Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilen MA, Bosse D, Coulomb-L'hermine A, Su X, Choueiri TK, Tannir NM, Malouf GG

J Immunother Cancer. 2018 Dec 27;6(1):159

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.

Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier É, Deville JL, Goupil MG, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthelemy P, Sella A, Fizazi K, Baciarello G, Fererro JM, Laguerre B, Verret B, Hans S, Oudard S

Eur Urol Oncol. 2018 Dec;1(6):467-475

Clinical utility of complex multi-platform profiling in metastatic cancer patients.

Garcia Foncillas J, Aftimos PG, Barthelemy P, Bellmunt J, Berchem G, Camps C, de Las Peñas R, Finzel A, Hervonen JP, Joensuu T, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, Perren TJ, Guitti G, Laes JF

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii480

Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (

Necchi A, Pouessel D, Leibowitz-Amit R, Flechon A, Gupta S, Barthelemy P, Maio M, Zhu X, Asatiani E, Serbest G, Zhen H, Loriot Y

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii319-viii320

Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium.

Sroussi M, Lorcet M, Tardy MP, Guerin M, Estrade F, Delva R, Barthelemy P, Lavaud P, Neuzillet Y, Penel N, Houede N, Pouessel D, Mussat E, Gross Goupil M, Gauthier H, Gobert A, Huillard O, Allory Y, Elaidi RT, Oudard S

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii321-viii322

TiNivo - tivozanib combined with nivolumab: Safety and efficacy in patients with metastatic renal cell carcinoma (mRCC).

Barthelemy P, Escudier B, Ravaud A, Negrier S, Needle MN, Albiges L

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii311

Management of non-metastatic castrate-resistant prostate cancer: A systematic review.

Loriot Y, Supiot S, Beauval JB, Schlürmann F, Pasticier G, Sargos P, Barthélémy P, Pignot G, Maillet D, Vincendeau S, Gross E, Ploussard G, Timsit MO, Borchiellini D

Cancer Treat. Rev.. 2018 Sep 21;70:223-231

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.

Guillot A, Joly C, Barthélémy P, Meriaux E, Negrier S, Pouessel D, Chevreau C, Mahammedi H, Houede N, Roubaud G, Gravis G, Tartas S, Albiges L, Vassal C, Oriol M, Tinquaut F, Espenel S, Bouleftour W, Culine S, Fizazi K

Clin Genitourin Cancer. 2018 Sep 6;:

Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer.

Lange M, Heutte N, Noal S, Rigal O, Kurtz JE, Lévy C, Allouache D, Rieux C, Lefel J, Clarisse B, Leconte A, Veyret C, Barthélémy P, Longato N, Tron L, Castel H, Eustache F, Giffard B, Joly F

Oncologist. 2018 Jun 22;:

Systemic treatments for high-risk localized prostate cancer.

Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D

Nat Rev Urol. 2018 May 15;:

The clinical impact of using complex molecular profiling strategies in routine oncology practice.

Laes JF, Aftimos P, Barthelemy P, Bellmunt J, Berchem G, Camps C, Peñas RL, Finzel A, García-Foncillas J, Hervonen P, Wahid I, Joensuu T, Kathan L, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, Odarchenko S, Perren TJ, Pienaar R, Regonesi C, Alkhayyat SS, El Kinge AR, Abulkhair O, Galal KM, Ghanem H, El Karak F, Garcia A, Ghitti G, Sadik H

Oncotarget. 2018 Apr 17;9(29):20282-20293

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B,

N. Engl. J. Med.. 2018 04 5;378(14):1277-1290

Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.

Beauval JB, Loriot Y, Hennequin C, Rozet F, Barthelemy P, Borchiellini D, Schlürmann Constans F, Gross E, Maillet D, Pasticier G, Pignot G, Timsit MO, Vincendeau S, Ploussard G, Sargos P

Crit. Rev. Oncol. Hematol.. 2018 Feb;122:144-149

Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.

Korenbaum C, Pierard L, Thiéry A, Story F, Lindner V, Lang H, Kurtz JE, Barthélémy P

Clin Genitourin Cancer. 2017 Dec 28;:

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L

Eur. J. Cancer. 2017 May;80:55-62

Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.

Burgy M, Barthélémy P, Lefevre F, Dupret-Bories A, Truntzer P, Korenbaum C, Flesch H, Bronner G, Borel C

Oncology. 2017 Apr;:

Primary CIC-DUX4 round cell sarcoma of the kidney: A treatment-refractory tumor with poor outcome.

Bergerat S, Barthelemy P, Mouracade P, Lang H, Saussine C, Lindner V, Jacqmin D

Pathol. Res. Pract.. 2017 Feb;213(2):154-160

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.

Oudard S, Joly F, Geoffrois L, Laguerre B, Houede N, Barthelemy P, Gross-Goupil M, Vano Y, Lucidarme O, Bidault F, Kelkouli N, Slimane K, Escudier B

Clin Genitourin Cancer. 2016 Dec;14(6):e595-e607

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.

Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F

Cancer Treat. Rev.. 2016 Sep;:

Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas.

Malouf GG, Compérat E, Yao H, Mouawad R, Lindner V, Rioux-Leclercq N, Verkarre V, Leroy X, Dainese L, Classe M, Descotes JL, Barthelemy P, Yacoub M, Rouprêt M, Bernhard JC, Creighton CJ, Spano JP, Su X, Khayat D

Sci Rep. 2016 Aug;6:30988

Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment.

Lange M, Heutte N, Rigal O, Noal S, Kurtz JE, Lévy C, Allouache D, Rieux C, Lefel J, Clarisse B, Veyret C, Barthélémy P, Longato N, Castel H, Eustache F, Giffard B, Joly F

Oncologist. 2016 Jul;:

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, Romieu G, Bonneterre J, Ferrero JM, Kerbrat P, Soulie P, Mouret-Reynier MA, Bachelot T, Lerebours F, Eymard JC, Deblock M, Lortholary A, Hardy-Bessard AC, Barthelemy P, Bonnefoi H, Charafe-Jauffret E, Bidard FC, Viens P, Lemonnier J, Pierga JY

Lancet Oncol.. 2016 May;17(5):600-11

Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.

Gravis G, Chanez B, Derosa L, Beuselinck B, Barthelemy P, Laguerre B, Brachet PE, Joly F, Escudier B, Harrison DJ, Laird A, Vasudev N, Ralph C, Larkin J, Lote H, Salem N, Walz J, Thomassin J, Sfumato P, Stewart GD, Boher JM,

Urol. Oncol.. 2016 Apr;34(4):167.e17-23